AccuMetab™ Human CYP2D6∗ 17 Enzyme, Catalytically Active

CAT#: ITS-0426-YL22
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2D6∗ 17 variant for precise pharmacogenetic Phase I profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Predominantly found in populations of African descent, the CYP2D6∗ 17 variant demonstrates altered substrate affinity and decreased catalytic turnover. Evaluating drug candidates against this specific polymorphism is necessary to support diverse clinical trial design and equitable therapeutic efficacy.
Key Features
African-prevalent pharmacogenetic variant model; Validates altered substrate affinities in vitro; Crucial for inclusive clinical trial safety scaling; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Phenotype Comparison, Polymorphism Impact
Research Areas
ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry